Myosin light chain kinase, smooth muscle

Description:

Description
  • Accession: Q15746
  • Swissprot: MYLK_HUMAN
  • Organism: Homo sapiens
  • Gene: MYLK
  • Target class: Kinase

Drug Relations:

bosutinib
a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases Bioactivity details MOA
fasudil
intracellular calcium antagonist Bioactivity details MOA
midostaurin
Midostaurin is a small molecule that inhibits multiple receptor tyrosine kinases. In vitro biochemical or cellular assays have shown that midostaurin or its major human active metabolites CGP62221 and CGP52421 inhibit the activity of wild type FLT3, FLT3 mutant kinases (ITD and TKD), KIT (wild type and D816V mutant), PDGFR-alfa/beta, VEGFR2, as well as members of the serine/threonine kinase PKC (protein kinase C) family. Midostaurin demonstrated the ability to inhibit FLT3 receptor signaling and cell proliferation, and it induced apoptosis in leukemic cells expressing ITD and TKD mutant FLT3 receptors or overexpressing wild type FLT3 and PDGF receptors. Midostaurin also demonstrated the ability to inhibit KIT signaling, cell proliferation and histamine release and induce apoptosis in mast cells. Bioactivity details MOA
nifedipine
A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Bioactivity details MOA
nintedanib
Bioactivity details MOA
ruboxistaurin
inhibits protein kinase C beta Bioactivity details MOA
ruxolitinib
a kinase inhibitor, inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2 which mediate the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function Bioactivity details MOA
sunitinib
An indole and pyrrole derivative that inhibits VEGFR-2 and PDGFR BETA RECEPTOR TYROSINE KINASES. It is used as an antineoplastic agent for the treatment of GASTROINTESTINAL STROMAL TUMORS, and for treatment of advanced or metastatic RENAL CELL CARCINOMA. Bioactivity details MOA